Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up – Still a Buy?

Ono Pharmaceutical Co. (OTCMKTS:OPHLFGet Free Report)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $13.38, but opened at $15.33. Ono Pharmaceutical shares last traded at $14.61, with a volume of 911 shares trading hands.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Strong Buy”.

Check Out Our Latest Stock Report on OPHLF

Ono Pharmaceutical Price Performance

The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.56 and a current ratio of 3.02. The company has a market capitalization of $6.87 billion, a price-to-earnings ratio of 14.76 and a beta of 0.34. The company has a 50-day moving average price of $14.32 and a 200-day moving average price of $14.73.

Ono Pharmaceutical Company Profile

(Get Free Report)

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.

Recommended Stories

Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.